[1]
. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain. Supplement. 1986:3():S1-226
[PubMed PMID: 3461421]
[2]
Robertson SA. What is pain? Journal of the American Veterinary Medical Association. 2002 Jul 15:221(2):202-5
[PubMed PMID: 12118579]
[3]
Woolf CJ. What is this thing called pain? The Journal of clinical investigation. 2010 Nov:120(11):3742-4. doi: 10.1172/JCI45178. Epub 2010 Nov 1
[PubMed PMID: 21041955]
[4]
Loeser JD, Melzack R. Pain: an overview. Lancet (London, England). 1999 May 8:353(9164):1607-9
[PubMed PMID: 10334273]
Level 3 (low-level) evidence
[5]
Manjiani D, Paul DB, Kunnumpurath S, Kaye AD, Vadivelu N. Availability and utilization of opioids for pain management: global issues. The Ochsner journal. 2014 Summer:14(2):208-15
[PubMed PMID: 24940131]
[6]
Okusanya BO, Asaolu IO, Ehiri JE, Kimaru LJ, Okechukwu A, Rosales C. Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review. Systematic reviews. 2020 Jul 28:9(1):167. doi: 10.1186/s13643-020-01425-3. Epub 2020 Jul 28
[PubMed PMID: 32723354]
Level 1 (high-level) evidence
[7]
Feng Y, He X, Yang Y, Chao D, Lazarus LH, Xia Y. Current research on opioid receptor function. Current drug targets. 2012 Feb:13(2):230-46
[PubMed PMID: 22204322]
[9]
Lötsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. Journal of pain and symptom management. 2005 May:29(5 Suppl):S90-103
[PubMed PMID: 15907650]
[10]
Stone AB, Urman RD, Kaye AD, Grant MC. Labeling Morphine Milligram Equivalents on Opioid Packaging: a Potential Patient Safety Intervention. Current pain and headache reports. 2018 May 31:22(7):46. doi: 10.1007/s11916-018-0695-3. Epub 2018 May 31
[PubMed PMID: 29855852]
[11]
Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2022 Nov 4:71(3):1-95. doi: 10.15585/mmwr.rr7103a1. Epub 2022 Nov 4
[PubMed PMID: 36327391]
Level 1 (high-level) evidence
[12]
Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Current neuropharmacology. 2006 Jul:4(3):239-57
[PubMed PMID: 18615144]
[13]
Rice AS, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins, leukotrienes, and essential fatty acids. 2002 Feb-Mar:66(2-3):243-56
[PubMed PMID: 12052040]
[14]
Anthony AT, Rahmat S, Sangle P, Sandhu O, Khan S. Cannabinoid Receptors and Their Relationship With Chronic Pain: A Narrative Review. Cureus. 2020 Sep 14:12(9):e10436. doi: 10.7759/cureus.10436. Epub 2020 Sep 14
[PubMed PMID: 33072446]
Level 3 (low-level) evidence
[15]
Choi S, Huang BC, Gamaldo CE. Therapeutic Uses of Cannabis on Sleep Disorders and Related Conditions. Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society. 2020 Jan:37(1):39-49. doi: 10.1097/WNP.0000000000000617. Epub
[PubMed PMID: 31895189]
[17]
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical pharmacokinetics. 2003:42(4):327-60
[PubMed PMID: 12648025]
[18]
Cunha-Oliveira T, Rego AC, Oliveira CR. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain research reviews. 2008 Jun:58(1):192-208. doi: 10.1016/j.brainresrev.2008.03.002. Epub 2008 Mar 27
[PubMed PMID: 18440072]
[19]
LaLumiere RT, Kalivas PW. Glutamate release in the nucleus accumbens core is necessary for heroin seeking. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2008 Mar 19:28(12):3170-7. doi: 10.1523/JNEUROSCI.5129-07.2008. Epub
[PubMed PMID: 18354020]
[20]
Ivanov IS, Schulz KP, Palmero RC, Newcorn JH. Neurorobiology and evidence-based biological treatments for substance abuse disorders. CNS spectrums. 2006 Nov:11(11):864-77
[PubMed PMID: 17075558]
[22]
Birnbaum HG, White AG, Reynolds JL, Greenberg PE, Zhang M, Vallow S, Schein JR, Katz NP. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. The Clinical journal of pain. 2006 Oct:22(8):667-76
[PubMed PMID: 16988561]
Level 3 (low-level) evidence
[23]
Karow A, Verthein U, Krausz M, Schafer I. Association of personality disorders, family conflicts and treatment with quality of life in opiate addiction. European addiction research. 2008:14(1):38-46. doi: 10.1159/000110409. Epub 2008 Jan 7
[PubMed PMID: 18182771]
Level 2 (mid-level) evidence
[24]
Candiotti KA, Gitlin MC. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Current medical research and opinion. 2010 Jul:26(7):1677-84. doi: 10.1185/03007995.2010.483941. Epub
[PubMed PMID: 20465361]
Level 3 (low-level) evidence
[25]
Dumas EO, Pollack GM. Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. The AAPS journal. 2008 Dec:10(4):537-51. doi: 10.1208/s12248-008-9056-1. Epub 2008 Nov 7
[PubMed PMID: 18989788]
Level 3 (low-level) evidence
[26]
Szigethy E, Knisely M, Drossman D. Opioid misuse in gastroenterology and non-opioid management of abdominal pain. Nature reviews. Gastroenterology & hepatology. 2018 Mar:15(3):168-180. doi: 10.1038/nrgastro.2017.141. Epub 2017 Nov 15
[PubMed PMID: 29139482]
[27]
Wolff K, Perez-Montejano R. Opioid neonatal abstinence syndrome: controversies and implications for practice. Current drug abuse reviews. 2014:7(1):44-58
[PubMed PMID: 25323126]
[28]
Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Experimental and clinical psychopharmacology. 2008 Oct:16(5):405-16. doi: 10.1037/a0013628. Epub
[PubMed PMID: 18837637]
Level 3 (low-level) evidence
[29]
Weller AE, Crist RC, Reiner BC, Doyle GA, Berrettini WH. Neonatal Opioid Withdrawal Syndrome (NOWS): A Transgenerational Echo of the Opioid Crisis. Cold Spring Harbor perspectives in medicine. 2021 Mar 1:11(3):. doi: 10.1101/cshperspect.a039669. Epub 2021 Mar 1
[PubMed PMID: 32229609]
Level 3 (low-level) evidence
[30]
Leyenaar JK, Schaefer AP, Wasserman JR, Moen EL, O'Malley AJ, Goodman DC. Infant Mortality Associated With Prenatal Opioid Exposure. JAMA pediatrics. 2021 Jul 1:175(7):706-714. doi: 10.1001/jamapediatrics.2020.6364. Epub
[PubMed PMID: 33843963]
[31]
ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. Phytochemistry of Cannabis sativa L. Progress in the chemistry of organic natural products. 2017:103():1-36. doi: 10.1007/978-3-319-45541-9_1. Epub
[PubMed PMID: 28120229]
[32]
Vučković S, Srebro D, Vujović KS, Vučetić Č, Prostran M. Cannabinoids and Pain: New Insights From Old Molecules. Frontiers in pharmacology. 2018:9():1259. doi: 10.3389/fphar.2018.01259. Epub 2018 Nov 13
[PubMed PMID: 30542280]
[33]
Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2008 Jun 17:178(13):1669-78. doi: 10.1503/cmaj.071178. Epub
[PubMed PMID: 18559804]
Level 1 (high-level) evidence
[34]
Romero-Sandoval EA, Kolano AL, Alvarado-Vázquez PA. Cannabis and Cannabinoids for Chronic Pain. Current rheumatology reports. 2017 Oct 5:19(11):67. doi: 10.1007/s11926-017-0693-1. Epub 2017 Oct 5
[PubMed PMID: 28983880]
[35]
Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B, Lintzeris N, Khor KE, Farrell M, Smith A, Le Foll B. Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2017 Aug:42(9):1752-1765. doi: 10.1038/npp.2017.51. Epub 2017 Mar 22
[PubMed PMID: 28327548]
Level 1 (high-level) evidence
[36]
Hashemi D, Gray K. Cannabis Use Disorder in Adolescents. Child and adolescent psychiatric clinics of North America. 2023 Jan:32(1):13-20. doi: 10.1016/j.chc.2022.06.001. Epub 2022 Oct 22
[PubMed PMID: 36410900]
[37]
Connor JP, Stjepanović D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. Nature reviews. Disease primers. 2021 Feb 25:7(1):16. doi: 10.1038/s41572-021-00247-4. Epub 2021 Feb 25
[PubMed PMID: 33627670]
[38]
Zehra A, Burns J, Liu CK, Manza P, Wiers CE, Volkow ND, Wang GJ. Cannabis Addiction and the Brain: a Review. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2018 Dec:13(4):438-452. doi: 10.1007/s11481-018-9782-9. Epub 2018 Mar 19
[PubMed PMID: 29556883]
[39]
Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. The journal of pain. 2016 Jun:17(6):739-44. doi: 10.1016/j.jpain.2016.03.002. Epub 2016 Mar 19
[PubMed PMID: 27001005]
Level 2 (mid-level) evidence
[40]
Zhang MW, Ho RC. The Cannabis Dilemma: A Review of Its Associated Risks and Clinical Efficacy. Journal of addiction. 2015:2015():707596. doi: 10.1155/2015/707596. Epub 2015 Oct 11
[PubMed PMID: 26539302]
[41]
Metz TD, Allshouse AA, Hogue CJ, Goldenberg RL, Dudley DJ, Varner MW, Conway DL, Saade GR, Silver RM. Maternal marijuana use, adverse pregnancy outcomes, and neonatal morbidity. American journal of obstetrics and gynecology. 2017 Oct:217(4):478.e1-478.e8. doi: 10.1016/j.ajog.2017.05.050. Epub 2017 May 31
[PubMed PMID: 28578174]
[42]
Nader DA, Sanchez ZM. Effects of regular cannabis use on neurocognition, brain structure, and function: a systematic review of findings in adults. The American journal of drug and alcohol abuse. 2018:44(1):4-18. doi: 10.1080/00952990.2017.1306746. Epub 2017 May 12
[PubMed PMID: 28498718]
Level 1 (high-level) evidence
[43]
Carr D, Schatman M. Cannabis for Chronic Pain: Not Ready for Prime Time. American journal of public health. 2019 Jan:109(1):50-51. doi: 10.2105/AJPH.2018.304593. Epub
[PubMed PMID: 32941762]
[44]
Piper BJ, Beals ML, Abess AT, Nichols SD, Martin MW, Cobb CM, DeKeuster RM. Chronic pain patients' perspectives of medical cannabis. Pain. 2017 Jul:158(7):1373-1379. doi: 10.1097/j.pain.0000000000000899. Epub
[PubMed PMID: 28328576]
Level 3 (low-level) evidence
[45]
Abu-Sawwa R, Scutt B, Park Y. Emerging Use of Epidiolex (Cannabidiol) in Epilepsy. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2020:25(6):485-499. doi: 10.5863/1551-6776-25.6.485. Epub
[PubMed PMID: 32839652]
[46]
Shah S, Schwenk ES, Sondekoppam RV, Clarke H, Zakowski M, Rzasa-Lynn RS, Yeung B, Nicholson K, Schwartz G, Hooten WM, Wallace M, Viscusi ER, Narouze S. ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids. Regional anesthesia and pain medicine. 2023 Mar:48(3):97-117. doi: 10.1136/rapm-2022-104013. Epub 2023 Jan 3
[PubMed PMID: 36596580]
Level 3 (low-level) evidence
[47]
Imran M, Khan SA, Alshammari MK, Alqahtani AM, Alanazi TA, Kamal M, Jawaid T, Ghoneim MM, Alshehri S, Shakeel F. Discovery, Development, Inventions and Patent Review of Fexinidazole: The First All-Oral Therapy for Human African Trypanosomiasis. Pharmaceuticals (Basel, Switzerland). 2022 Jan 21:15(2):. doi: 10.3390/ph15020128. Epub 2022 Jan 21
[PubMed PMID: 35215241]
[48]
Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Sep 1:18(17):4785-93. doi: 10.1158/1078-0432.CCR-12-0110. Epub 2012 Aug 7
[PubMed PMID: 22872575]
[49]
Vázquez M, Guevara N, Maldonado C, Guido PC, Schaiquevich P. Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain. BioMed research international. 2020:2020():3902740. doi: 10.1155/2020/3902740. Epub 2020 Aug 13
[PubMed PMID: 32855964]
[50]
MacCallum CA, Eadie L, Barr AM, Boivin M, Lu S. Practical Strategies Using Medical Cannabis to Reduce Harms Associated With Long Term Opioid Use in Chronic Pain. Frontiers in pharmacology. 2021:12():633168. doi: 10.3389/fphar.2021.633168. Epub 2021 Apr 30
[PubMed PMID: 33995035]
[51]
Araujo AM, Gómez M, Pascual J, Castañeda M, Pezonaga L, Borque JL. [Treatment of pain in the oncology patient]. Anales del sistema sanitario de Navarra. 2004:27 Suppl 3():63-75
[PubMed PMID: 15723106]
[52]
Bilal M, Chatila A, Siddiqui MT, Al-Hanayneh M, Shah AR, Desai M, Wadhwa V, Parupudi S, Casey BW, Krishnan K, Hernandez-Barco YG. Rising Prevalence of Opioid Use Disorder and Predictors for Opioid Use Disorder Among Hospitalized Patients With Chronic Pancreatitis. Pancreas. 2019 Nov/Dec:48(10):1386-1392. doi: 10.1097/MPA.0000000000001430. Epub
[PubMed PMID: 31688606]
Level 3 (low-level) evidence
[53]
Nalamachu S. An overview of pain management: the clinical efficacy and value of treatment. The American journal of managed care. 2013 Nov:19(14 Suppl):s261-6
[PubMed PMID: 24494608]
Level 3 (low-level) evidence
[54]
Fitzgibbon DR. Clinical use of opioids for cancer pain. Current pain and headache reports. 2007 Aug:11(4):251-8
[PubMed PMID: 17686387]
[55]
Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. The Clinical journal of pain. 2008 Jul-Aug:24(6):469-78. doi: 10.1097/AJP.0b013e31816b2f26. Epub
[PubMed PMID: 18574357]
[56]
Hill MV, McMahon ML, Stucke RS, Barth RJ Jr. Wide Variation and Excessive Dosage of Opioid Prescriptions for Common General Surgical Procedures. Annals of surgery. 2017 Apr:265(4):709-714. doi: 10.1097/SLA.0000000000001993. Epub
[PubMed PMID: 27631771]
[57]
Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Science & practice perspectives. 2002 Jul:1(1):13-20
[PubMed PMID: 18567959]
[58]
Corroon JM Jr, Mischley LK, Sexton M. Cannabis as a substitute for prescription drugs - a cross-sectional study. Journal of pain research. 2017:10():989-998. doi: 10.2147/JPR.S134330. Epub 2017 May 2
[PubMed PMID: 28496355]
Level 2 (mid-level) evidence
[59]
Lim G, Sung B, Ji RR, Mao J. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain. 2003 Sep:105(1-2):275-83
[PubMed PMID: 14499445]
[60]
Hsieh GC, Pai M, Chandran P, Hooker BA, Zhu CZ, Salyers AK, Wensink EJ, Zhan C, Carroll WA, Dart MJ, Yao BB, Honore P, Meyer MD. Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. British journal of pharmacology. 2011 Jan:162(2):428-40. doi: 10.1111/j.1476-5381.2010.01046.x. Epub
[PubMed PMID: 20880025]
[61]
Turcotte C, Blanchet MR, Laviolette M, Flamand N. The CB(2) receptor and its role as a regulator of inflammation. Cellular and molecular life sciences : CMLS. 2016 Dec:73(23):4449-4470
[PubMed PMID: 27402121]
[62]
Vincent L, Vang D, Nguyen J, Benson B, Lei J, Gupta K. Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation. Haematologica. 2016 May:101(5):566-77. doi: 10.3324/haematol.2015.136523. Epub 2015 Dec 24
[PubMed PMID: 26703965]
[63]
Barlowe TS, Koliani-Pace JL, Smith KD, Gordon SR, Gardner TB. Effects of Medical Cannabis on Use of Opioids and Hospital Visits by Patients With Painful Chronic Pancreatitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2019 Nov:17(12):2608-2609.e1. doi: 10.1016/j.cgh.2019.01.018. Epub 2019 Jan 18
[PubMed PMID: 30664949]
[64]
Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm reduction journal. 2019 Jan 28:16(1):9. doi: 10.1186/s12954-019-0278-6. Epub 2019 Jan 28
[PubMed PMID: 30691503]
[65]
Vigil JM, Stith SS, Adams IM, Reeve AP. Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study. PloS one. 2017:12(11):e0187795. doi: 10.1371/journal.pone.0187795. Epub 2017 Nov 16
[PubMed PMID: 29145417]
[66]
Golub V, Reddy DS. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders. Advances in experimental medicine and biology. 2021:1264():93-110. doi: 10.1007/978-3-030-57369-0_7. Epub
[PubMed PMID: 33332006]
Level 3 (low-level) evidence
[67]
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S, Cannabidiol in Dravet Syndrome Study Group. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. The New England journal of medicine. 2017 May 25:376(21):2011-2020. doi: 10.1056/NEJMoa1611618. Epub
[PubMed PMID: 28538134]
[68]
Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, O'Callaghan FJ, Wong M, Sahebkar F, Checketts D, Knappertz V, GWPCARE6 Study Group. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA neurology. 2021 Mar 1:78(3):285-292. doi: 10.1001/jamaneurol.2020.4607. Epub
[PubMed PMID: 33346789]
Level 1 (high-level) evidence
[69]
Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, Dean L, Kane M. Dronabinol Therapy and CYP2C9 Genotype. Medical Genetics Summaries. 2012:():
[PubMed PMID: 33211456]
[70]
Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: Therapeutic Use in Clinical Practice. International journal of molecular sciences. 2022 Mar 19:23(6):. doi: 10.3390/ijms23063344. Epub 2022 Mar 19
[PubMed PMID: 35328765]
[71]
Maurer GE, Mathews NM, Schleich KT, Slayman TG, Marcussen BL. Understanding Cannabis-Based Therapeutics in Sports Medicine. Sports health. 2020 Nov/Dec:12(6):540-546. doi: 10.1177/1941738120956604. Epub 2020 Sep 16
[PubMed PMID: 32936058]
Level 3 (low-level) evidence
[72]
Mack A, Joy J. Marijuana as Medicine? The Science Beyond the Controversy. 2000:():
[PubMed PMID: 25077214]
Level 3 (low-level) evidence
[73]
Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. Journal of the American Medical Directors Association. 2003 Jan-Feb:4(1):9-15
[PubMed PMID: 12807591]
[74]
Berger BA, Stolz U, Colvin J, Otten EJ. Epidemiology of cannabidiol related cases reported in the National Poison Data System - 2019-2020. The American journal of emergency medicine. 2021 Oct:48():218-223. doi: 10.1016/j.ajem.2021.04.065. Epub 2021 Apr 23
[PubMed PMID: 33975134]
Level 3 (low-level) evidence
[75]
Huygen F, Kallewaard JW, van Tulder M, Van Boxem K, Vissers K, van Kleef M, Van Zundert J. "Evidence-Based Interventional Pain Medicine According to Clinical Diagnoses": Update 2018. Pain practice : the official journal of World Institute of Pain. 2019 Jul:19(6):664-675. doi: 10.1111/papr.12786. Epub 2019 May 2
[PubMed PMID: 30957944]
[76]
Thorlund JB, Simic M, Pihl K, Berthelsen DB, Day R, Koes B, Juhl CB. Similar Effects of Exercise Therapy, Nonsteroidal Anti-inflammatory Drugs, and Opioids for Knee Osteoarthritis Pain: A Systematic Review with Network Meta-analysis. The Journal of orthopaedic and sports physical therapy. 2022 Apr:52(4):207-216. doi: 10.2519/jospt.2022.10490. Epub
[PubMed PMID: 35442752]
Level 1 (high-level) evidence
[77]
Farag HM, Yunusa I, Goswami H, Sultan I, Doucette JA, Eguale T. Comparison of Amitriptyline and US Food and Drug Administration-Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis. JAMA network open. 2022 May 2:5(5):e2212939. doi: 10.1001/jamanetworkopen.2022.12939. Epub 2022 May 2
[PubMed PMID: 35587348]
Level 1 (high-level) evidence
[78]
Watson JC, Sandroni P. Central Neuropathic Pain Syndromes. Mayo Clinic proceedings. 2016 Mar:91(3):372-85. doi: 10.1016/j.mayocp.2016.01.017. Epub
[PubMed PMID: 26944242]
[79]
Phillips E, Gazmararian J. Implications of prescription drug monitoring and medical cannabis legislation on opioid overdose mortality. Journal of opioid management. 2017 Jul/Aug:13(4):229-239. doi: 10.5055/jom.2017.0391. Epub
[PubMed PMID: 28953315]